リソース ライブラリ

Many small-to-mid sized companies want to know: how much should they invest in launch?

Syneos Health conducted an in-depth analysis of pre-launch and launch Selling, General and Administrative (SG&A) spend of emerging companies launching their first product, which revealed that many companies find themselves either underfunding and subsequently underperforming in the market, or overfunding and incurring costs that do not add incremental value to commercial success.  View full results here. 

Listen to the podcast here

Diving deeper into the issue, Syneos Health conducted a survey of over 300 Biopharma and Finance/Advisory Executives – followed by an interactive live workshop at the Biotech Showcase conference in San Francisco – to help understand their experiences with emerging company launches and pre-launch SG&A spend.  Contact us to receive the full report, coming soon.